Xu et al. discovered that the overexpression of TEAD4 correlated with poor prognosis of glioma, but they ignored the impact of recognized factors such as IDH mutation and 1p19q co-deletion on the prognosis of glioma and had not considered the difference in outcomes between LGGs and GBM [26]. The gene discussed is TEAD4; the disease is central nervous system cancer.